COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER

被引：0
|
作者：
Guan, X. [1 ]
Li, H. C. [1 ]
Xia, Y. [2 ]
Yang, Q. [2 ]
Ma, A. X. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Peoples R China
[2] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE197
引用
下载
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [2] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [4] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [5] A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL
    Silva Miguel, L.
    Pinheiro, B.
    Lopes, R.
    Revil, C.
    Monteiro, I
    Borges, M.
    VALUE IN HEALTH, 2022, 25 (01) : S69 - S70
  • [6] Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Shanshan Hu
    Yilai Wu
    Jiajie Luan
    Shuowen Wang
    Guorong Fan
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17933 - 17942
  • [7] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE FOR THE ADJUVANT TREAT OF PATIENTS WITH RESIDUAL INVASIVE HER2+EARLY BREAST CANCER IN GREECE
    Naoum, V
    Antonaki, M.
    Kakouros, M.
    Hansen, S. A.
    Ouzounelli, M.
    Tziarou, N.
    VALUE IN HEALTH, 2022, 25 (12) : S173 - S173
  • [8] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [9] Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Hu, Shanshan
    Wu, Yilai
    Luan, Jiajie
    Wang, Shuowen
    Fan, Guorong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 17933 - 17942
  • [10] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024,
12345